Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer
- PMID: 31471138
- DOI: 10.1016/j.eururo.2019.08.014
Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer
Abstract
Context: Progress achieved in the treatment of prostate cancer (PCa) with surgical, radiation, and hormonal therapies has drastically reduced mortality from this disease. Yet, patients with advanced PCa have few, if any, curative options. Recent success in treating patients with hematological malignancies of B-cell origin using T cells engineered to express chimeric antigen receptors (CARs) has inspired multiple groups worldwide to adapt this approach to the problem of late-stage PCa.
Objective: To summarize the available clinical results for CAR T-cell therapy of PCa and discuss future technological advancements in the CAR T-cell field that may help patients with metastatic PCa.
Evidence acquisition: A literature review was conducted of clinical trial data, abstracts presented at recent oncology conferences, as well as reports highlighting critical bottlenecks of CAR T-cell therapy that became apparent from preclinical and clinical studies.
Evidence synthesis: Current understanding of why CAR T-cell therapy may fail, particularly in the context of solid cancers, is as follows. First, a CAR design that provides potent activity and persistence of engineered T cells in the hostile tumor microenvironment is a must. The choice of the targetable epitope(s) is critical to counteract tumor antigen escape. Preclinical and clinical evidence indicates that the efficacy of CAR T-cell therapy can be enhanced significantly in combination with other therapeutic approaches. We propose that several improvements to CAR design and patient conditioning, such as unbiased identification of novel PCa-specific CAR targets, use of next-generation (multispecific, resistant to the tumor microenvironment, and with prolonged persistence) CAR T-cell products, and combination therapies may translate into improved patient outcomes and more durable responses.
Conclusions: Although significant preclinical experience of testing CAR T cells in solid cancer models has identified important technological and biological bottlenecks, information from clinical trials, particularly those focusing on the PCa, will be instrumental to the rational design of advanced CAR T therapies that will be both safe and effective in patients with advanced PCa.
Patient summary: So far, chimeric antigen receptor (CAR) T-cell therapy has not shown significant activity in patients with metastatic prostate cancer (PCa). CAR T-cell products used for such trials represent one of the pioneering efforts to adapt this technology to the problem of metastatic PCa. In retrospect, both CAR design and cell composition appear to have been suboptimal to expect strong patient responses. Given the impressive results of CAR-based approaches observed in preclinical models of solid cancers, emerging CAR T-cell products are expected to be more successful in the clinic. Here, we discuss the challenges that need to be overcome to boost the efficacy of PCa-targeted CAR T-cell therapy and call for dialogue between clinicians and cell biologists to address these challenges.
Keywords: Chimeric antigen receptor; Immunotherapy; Prostate cancer.
Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Comment in
-
Chimeric Antigen Receptor T-cell Therapy in Prostate Cancer: Reality or Folly?Eur Urol. 2020 Mar;77(3):309-310. doi: 10.1016/j.eururo.2019.12.002. Epub 2019 Dec 19. Eur Urol. 2020. PMID: 31864760 No abstract available.
Similar articles
-
Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.Int J Mol Sci. 2021 Jan 11;22(2):640. doi: 10.3390/ijms22020640. Int J Mol Sci. 2021. PMID: 33440664 Free PMC article. Review.
-
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.BioDrugs. 2015 Apr;29(2):75-89. doi: 10.1007/s40259-015-0122-9. BioDrugs. 2015. PMID: 25859858 Free PMC article. Review.
-
Chimeric antigen receptor-engineered T-cell therapy for liver cancer.Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):301-309. doi: 10.1016/j.hbpd.2018.05.005. Epub 2018 May 24. Hepatobiliary Pancreat Dis Int. 2018. PMID: 29861325 Review.
-
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.Cells. 2020 Jun 2;9(6):1382. doi: 10.3390/cells9061382. Cells. 2020. PMID: 32498368 Free PMC article.
-
Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead.Cells. 2021 Jun 9;10(6):1450. doi: 10.3390/cells10061450. Cells. 2021. PMID: 34207884 Free PMC article. Review.
Cited by
-
HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo.Genes Immun. 2024 Jun;25(3):201-208. doi: 10.1038/s41435-024-00275-6. Epub 2024 May 3. Genes Immun. 2024. PMID: 38702509 Free PMC article.
-
Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.Medicina (Kaunas). 2023 Dec 18;59(12):2198. doi: 10.3390/medicina59122198. Medicina (Kaunas). 2023. PMID: 38138301 Free PMC article. Review.
-
Revolutionizing cancer immunotherapy in solid tumor: CAR engineering and single-cell sequencing insights.Front Immunol. 2023 Nov 23;14:1310285. doi: 10.3389/fimmu.2023.1310285. eCollection 2023. Front Immunol. 2023. PMID: 38090577 Free PMC article. Review.
-
Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.Curr Issues Mol Biol. 2023 Nov 12;45(11):9019-9038. doi: 10.3390/cimb45110566. Curr Issues Mol Biol. 2023. PMID: 37998743 Free PMC article. Review.
-
Current status and future prospects of chimeric antigen receptor-T cell therapy in lymphoma research: A bibliometric analysis.Hum Vaccin Immunother. 2023 Dec 15;19(3):2267865. doi: 10.1080/21645515.2023.2267865. Epub 2023 Oct 16. Hum Vaccin Immunother. 2023. PMID: 37846106 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous